Assessment of efficacy and safety of desvenlafaxine versus escitalopram in major depressive disorder with symptoms of anxiety:a randomized clinical trial

Department of Pharmacology IPGMER Kolkata0 个研究点目标入组 85 人开始时间: 待定最近更新: 2023年2月6日

试验速览

暂无简介。

•subjects of major depressive disorder with symptoms of anxiety with HAM score of seven to eighteen
•baseline HAMA score more than or equal to twelve
•Subjects must be willing to give written informed consent

•subjects with age less tha eighteen or more than sixty
•Pregnant and lactating women
•Baseline HAMD score less than seven or more than eighteen
•Baseline HAMA score less than 12
•Subjects with psychotic features
•Subjects with suicidality catatonic features
•Subjects on any antidepressant medications in the last two months
•Subjects with concurrent severe medical disorders like uncontrolled diabetes hypertension ischemic heart disease chronic renal failure cirrhosis any malignancy etc
•Subjects with history of substance abuse in the last two years
•Subjects with mixed depression and anxiety disorder or any other episodes of other mood disorder bipolar disorder dysthymia etc
•Subjects with any other psychiatric disorders
•Subjects on other concurrent medications known to have drug interact with the study medications like other SSRI SNRI tricyclic antidepressants etc
•Subjects with past history of anaphylaxis or hypersensitivity to any of the study medications

发起方

Department of Pharmacology IPGMER Kolkata